Primary Outcomes

Description: Bacterial pathogens, as identified by bacteriological methods, including (but not necessarily limited to) Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii.

Measure: Occurrence of potential bacterial in sputum of stable COPD patients.

Time: Over the course of 1 year

---

Description: Bacterial pathogens, as identified by bacteriological methods, including (but not necessarily limited to) Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter baumannii.

Measure: Occurrence of potential bacterial in sputum during AECOPD.

Time: Over the course of 1 year

---

Description: Viral pathogens, as identified by PCR, including (but not necessarily limited to) Respiratory syncytial virus (RSV), parainfluenza virus, enterovirus/ rhinovirus, metapneumovirus, influenza virus, adenovirus, bocavirus and coronavirus and by rhinovirus quantitative RT-PCR.

Measure: Occurrence of viral pathogens in sputum of stable COPD patients.

Time: Over the course of 1 year

---

Description: Viral pathogens, as identified by PCR, including (but not necessarily limited to) Respiratory syncytial virus (RSV), parainfluenza virus, enterovirus/ rhinovirus, metapneumovirus, influenza virus, adenovirus, bocavirus and coronavirus and by rhinovirus quantitative RT-PCR.

Measure: Occurrence of viral pathogens in sputum during AECOPD.

Time: Over the course of 1 year

---

Secondary Outcomes

Description: Including (but not necessarily limited to) H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus and P. aeruginosa. The proportion of sputum samples obtained at each confirmed stable/AECOPD visit and positive for specific bacterial pathogens by PCR will be computed with 95% confidence intervals.

Measure: Occurrence of potential bacterial pathogens in sputum of stable COPD patients and during AECOPD, as measured by real-time qualitative PCR/ quantitative PCR and compared to data from bacteriological methods.

Time: Over the course of 1 year

---

Description: The proportion of sputum samples obtained at each AECOPD visit and positive for specific bacterial/viral pathogens by bacteriological methods and PCR, respectively (overall and by bacterial/viral species) will be computed with 95% confidence intervals by any severity (mild, moderate and severe).

Measure: Occurrence of potential bacterial and viral pathogens (overall and by species) in sputum during AECOPD by severity of AECOPD.

Time: Over the course of 1 year

---

Description: The proportion of sputum samples obtained at each confirmed stable visit and positive for bacterial/viral pathogens by bacteriological methods and PCR, respectively (overall and by bacterial / viral species) will be computed with 95% confidence intervals by Gold grade at enrolment.

Measure: Occurrence of potential bacterial and viral pathogens (overall and by species) in sputum of stable COPD patients by GOLD grade.

Time: Over the course of 1 year

---

Description: The following incidence rates will be computed, with 95% confidence intervals (CI): All-cause AECOPD. AECOPD having sputum containing bacterial pathogens found by PCR or by bacteriological methods or by both methods (overall and by, but not limited to, the following bacterial species: H. influenzae, M. catarrhalis, S. pneumoniae, S. aureus, and P. aeruginosa). The 95% CI of the incidence rate will be computed using a model which accounts for repeated events. The incidence rates described above will also be computed for mild, moderate severe AECOPD and by GOLD grade at enrolment.

Measure: Incident rate (per subject per year) of any AECOPD overall and by GOLD grade.

Time: Over the course of 1 year

---

Description: Classification of severity according to the intensity of medical intervention required: mild: controlled with an increase in dosage of regular medications; moderate: requires treatment with systemic corticosteroids and/ or antibiotics; severe: requires hospitalisation.

Measure: Number of mild, moderate or severe AECOPD overall and by GOLD grade.

Time: Over the course of 1 year

---

Description: Descriptive statistics (median, mean, range, standard deviation, first and third quartiles) on the number of days of AECOPD episodes will be presented.

Measure: Number of days of AECOPD episodes overall and by AECOPD severity.

Time: Over the course of 1 year

---

Description: Descriptive statistics (median, mean, range, standard deviation, first and third quartiles) on the CAT scores will be tabulated at each respective visit.

Measure: COPD assessment test (CAT) score in stable COPD patients and during AECOPD.

Time: Over the course of 1 year

---

Description: Descriptive statistics (median, mean, range, standard deviation, first and third quartiles) on the SGRQ-C scores will be tabulated at each respective visit.

Measure: St. George's Respiratory Questionnaire (SGRQ-C) score in stable COPD patients.

Time: Over the course of 1 year

---

Description: The spirometric classification of airflow limitation in COPD patients is based on post-bronchodilator FEV1. Summary statistics (mean, median, standard deviation, maximum and minimum) on post bronchodilator FEV1% of predicted normal value will be tabulated at each respective visit.

Measure: Forced expiratory volume in 1 second (FEV1%) of predicted normal value in stable COPD patients.

Time: At Pre-Month 0 and Month 12

---

Description: Healthcare use for each COPD patient will be obtained through review of the subject's medical record (aided by subject self-reporting). Healthcare utilisation includes all unscheduled visits to a physician office, visits to urgent care, visits to emergency department, and hospitalizations.

Measure: Assessment of the Healthcare utilization.

Time: Over the course of 1 year

---

Primary Outcomes

Description: The exacerbation rate is based on exacerbations reported by the investigator over 52 weeks.

Measure: Moderate or severe COPD exacerbation rate ratio (tezepelumab vs placebo)

Time: Over 52 Weeks

---

Secondary Outcomes

Description: Time to first occurrence of moderate/severe exacerbation post randomization. Outcome measures: Hazard ratio

Measure: Time to first moderate or severe COPD exacerbation

Time: By Week 52

---

Description: Proportion of subjects with at least one moderate/severe exacerbation reported by the Investigator over 52 weeks Outcome measure: Odds Ratio

Measure: Proportion with at least one moderate/severe COPD exacerbation

Time: Over 52 Weeks

---

Description: The severe exacerbation rate is based on severe exacerbations reported by the Investigator over 52 weeks.

Measure: Severe COPD exacerbation rate ratio (tezepelumab vs. placebo)

Time: Over 52 Weeks

---

Description: Difference in change from baseline in pre-BD forced expiratory volume in 1 second (FEV1) in tezepelumab arm as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of forced expiration.

Measure: Change from baseline in pre-bronchodilator (pre-BD) forced expiratory volume in 1 second (FEV1)

Time: Baseline, Week 52

---

Description: Proportion of subjects achieving a decrease of 4 units or more in the St. George's Respiratory Questionnaire (SGRQ) total score at Week 52, i.e. minimum clinically important difference (MCID). Outcome measure: odds ratio

Measure: Change in respiratory health status/health-related quality of life

Time: Baseline, Week 52

---

Description: Difference (tezepelumab vs. placebo) in SGRQ from baseline at Week 52. SGRQ is a 50-item patient reported outcome questionnaire. The SGRQ total score is expressed as a percentage of overall impairment, in which 100% means the worst possible health status and 0% indicates the best possible health status. Likewise, the domain scores range from 0 to 100, with higher scores indicative of greater impairment. Decrease of 4 units is associated with a minimum clinically important difference (MCID).

Measure: Change from baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score

Time: Baseline, Week 52

---

Description: Difference (tezepelumab vs. placebo) in COPD assessment tool (CAT) from baseline at Week 52. CAT is an 8-item patient reported outcome questionnaire developed to measure the impact of COPD on health status. The instrument uses semantic differential six-point response scales. A CAT total score is the sum of item responses. The score ranges from 0 to 40, with higher scores indicating greater COPD impact on health status.

Measure: Change from baseline in the COPD Assessment Test (CAT) Total Score

Time: Baseline, Week 52

---

Description: Serum trough concentration of tezepelumab

Measure: Evaluate pharmacokinetics of tezepelumab

Time: Weeks 0, 4, 12, 24, 36, 52, 64

---

Description: Incidence of anti-drug antibodies (ADA)

Measure: Evaluate immunogenicity of tezepelumab

Time: Over 52 weeks

---

Primary Outcomes

Description: The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the period between randomization and 30 days following randomization The proportion is the number of patients with GOC documentation over the number of patients in each study arm. Documentation of goals-of-care discussions will be evaluated using our NLP/ML methods. Study staff will manually review and compare findings using a randomly-selected sample of charts using our standard EHR abstraction methods; manual chart abstraction will be the gold standard.

Measure: EHR documentation of Goals of Care discussions

Time: Assessed for the period between randomization and 30 days following randomization

---

Secondary Outcomes

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/ICU use: ICU admissions

Time: Assessed for the period between randomization and 30 days following randomization

---

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the ICU during their (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/ICU use: ICU length of stay

Time: Assessed for the period between randomization and 30 days following randomization

---

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the hospital during that (index) hospital stay will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care/Hospital use: Hospital length of stay

Time: Assessed for the period between randomization and 30 days following randomization

---

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of hospital readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care: Hospital Readmissions 30 days

Time: Assessed for the period between randomization and 30 days following randomization

---

Description: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.

Measure: Intensity of care: ICU Readmissions 30 days

Time: Assessed for the period between randomization and 30 days following randomization

---

Description: Costs for intervention vs. control will be reported in US dollars and identified from UW Medicine administrative financial databases. Costs will be reported for total hospital costs and disaggregated costs (direct-variable, direct fixed, indirect costs). Direct-variable costs will include supply and drug costs. Direct-fixed costs will include labor, clinical department administration, and overhead fees. Indirect costs represent services provided by cost centers not directly linked to patient care such as information technology and environmental services. Costs for ED (emergency department) days and ICU days will be similarly assessed.

Measure: Intensity of care: Healthcare costs

Time: 1 and 3 months after randomization

---

Description: From Washington State death certificates.

Measure: All-cause mortality at 1 year (safety outcome)

Time: 1 year after randomization

---

Other Outcomes

Description: Qualitative interviews after individual participation. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implementation (e.g., reach, maintenance, feasibility, inner and outer settings, individuals, and processes of care.) Individual constructs within these domains were chosen to fit this specific intervention and context.

Measure: Key Implementation Factors

Time: 3 months after randomization

---

Primary Outcomes

Description: Size of collected audio dataset measured as number of collected cough sounds, targeting ≥10,000 identified coughs.

Measure: Dataset size

Time: 14 days

---

Secondary Outcomes

Description: Identification of cough sounds by the existing mathematical model with ≥ 99% specificity and ≥ 60% sensitivity

Measure: Cough sound identification

Time: 14 days

---

Description: Increase in the sensitivity of the mathematical model to cough sounds to ≥ 70% while retaining the specificity of ≥ 99%

Measure: Improvement of the existing model

Time: 14 days

---

Description: Determination of the level of acceptance and satisfaction of the solution by patients by means of a Standard Usability Questionnaire to provide feedback. The score ranges from 10 to 50, higher score indicating a better usability.

Measure: Evaluate the usability of the application

Time: 14 days

---

Primary Outcomes

Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.

Measure: 7-day length of invasive mechanical ventilation (MV)

Time: Up to 7 days

---

Description: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: 30-day mortality rate

Time: Up to 30-day after randomization

---

Secondary Outcomes

Description: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of intensive care (ICU) transfer

Time: Up to 2 years

---

Description: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of invasive mechanical ventilation

Time: Up to 2 years

---

Description: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of tracheostomy

Time: Up to 2 years

---

Description: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test

Measure: Length of ICU stay

Time: Up to 2 years

---

Measure: Length of hospital stay

Time: Up 2 years

---

Primary Outcomes

Description: The primary outcome will be the change in number of moderate or severe AECOPD events over the 46 days from the 15th March, 2020 to 30th April, 2020 compared to the same 46 day period in 2019.

Measure: Change in COPD Exacerbation Rate

Time: 46 days

---

Secondary Outcomes

Measure: Change in number of Severe AECOPD events during period of interest in 2020 from same period in 2019.

Time: 46 days

---

Measure: Change in Moderate AECOPD events during period of interest in 2020 from same period in 2019.

Time: 46 days

---

Measure: Social contact changes during i) pre-lockdown and ii) lockdown period

Time: 46 days

---

Measure: Household contacts during i) pre-lockdown and ii) lockdown period

Time: 46 days

---

Measure: Household visitors during i) pre-lockdown and ii) lockdown period

Time: 46 days

---

Measure: Regular shopping behaviour during i) pre-lockdown and ii) lockdown period

Time: 46 days

---

Measure: Medication changes during i) pre-lockdown and ii) lockdown period

Time: 46 days

---

Measure: Reported change in regular medication usage during i) pre-lockdown and ii) lockdown period

Time: 46 days

---

Measure: Change in physical activity levels during i) pre-lockdown and ii) lockdown period

Time: 46 days

---

Measure: Change in anxiety levels during i) pre-lockdown and ii) lockdown period

Time: 46 days

---

Measure: Perceived fear of hospitalisation during COVID-19 period

Time: 46 days

---

Measure: Patient reported changes in perception of symptoms, need for hospitalisation and availability and safety of healthcare resources thought semi-structured interviews in 20 patients (nested qualitative study)

Time: 46 days

---

Measure: Association between changes in AECOPD event rate and changes in local air pollution during the COVID-19 lockdown

Time: 46 days

---

Primary Outcomes

Description: This is set on visit 3 (90 ± 5 days from the date of visit 1). The two groups of vaccination are compared for the primary endpoints which is composite. Patients who meet any of the following will be considered to meet the primary endpoint: Positive for the respiratory questionnaire endpoint when at least one of the following combination is met either at visit 2 and/or at visit 3: One situation definitively related to COVID-19 All four questions of symptoms possibly related to COVID-19 At least two questions of symptoms possibly related to COVID-19 as well as need for admission at the emergency department of any hospital and/or need for intake of antibiotics At least four questions of symptoms probably related to COVID-19 one of which is "need for admission at the emergency department of any hospital and/or need for intake of antibiotics" Positive IgG or IgM antibodies against SARS-CoV-2

Measure: Positive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 3.

Time: Visit 3 (90 +/- 5 days)

---

Secondary Outcomes

Description: The two groups of vaccination are compared for the primary endpoints which is composite (as defined at primary study endpoint) and meet a positive respiratory questionnaire endpoint on visit 4

Measure: Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 4

Time: Visit 4 (135 +/- 5 days)

---

Description: The two groups of vaccination are compared for the primary endpoints which is composite (as defined at primary study endpoint) and meet a positive respiratory questionnaire endpoint (as defined at primary study endpoint) on visit 5

Measure: Positive respiratory questionnaire endpoint consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 5

Time: Visit 5 (180 +/- 5 days)

---

Description: Prevalence of IgG/IgM against SARS-CoV-2 will be measured among the patients who failed the eligibility procedure and the patients that were eligible and were enrolled

Measure: Prevalence of IgG/IgM against SARS-CoV-2

Time: Screening Visit and Visit 3 (90 +/- 5 days)

---

Description: Itemized analysis of each of the components of the respiratory questionnaire on each study visit

Measure: Analysis of each of the components of the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19.

Time: Visit 2 (45 +/- 5 days), Visit 3 (90 +/- 5 days), Visit 4 (135 +/- 5 days), Visit 5 (180 +/- 5 days)

---

Description: The impact of new cardiovascular events between the two study groups (placebo and BCG) will be analyzed, though the collection of any cardiovascular events occured to the enrolled patients.

Measure: The impact of new cardiovascular events between the two study groups

Time: Visit 2 (45 +/- 5 days), Visit 3 (90 +/- 5 days), Visit 4 (135 +/- 5 days), Visit 5 (180 +/- 5 days)

---

Description: Differences in repeated measurements of arterial stiffness in visit 3 between the two sub-study groups (placebo or BCG) will be analyzed through the speed of the pulse wave velocity. Pulse wave velocity is measured in m/sec.

Measure: Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 3

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)

---

Description: Differences in repeated measurements of central arterial pressures and reflected waves in visit 3 between the two sub-study groups (placebo or BCG) will be measured non-invasively by pulse wave analysis. Central arterial pressure is measured in mmHg.

Measure: Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 3

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)

---

Description: Differences in repeated measurements of endothelial function in visit 3 between the two sub-study groups (placebo or BCG) will be measured by ultrasound measurement of endothelium-dependent flow-mediated dilatation and by nitrate-mediated dialatation. Endothelial function will be assessed by Flow Mediated Dilatation (FMD). Endothelium-dependent: diameter of the artery prior and after temporary ischemia in is measured in mm, nitrate-mediated: diameter of the artery prior and after nitrate administration is measured in mm

Measure: Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 3

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)

---

Description: Differences in repeated measurements of thickness of the medial carotid sheath in visit 3 between the two sub-study groups (placebo or BCG) will be measured by B-mode ultrasound examination. Intima-Media Thickness is measured in mm

Measure: Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 3

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)

---

Description: Differences in repeated measurements of arterial stiffness in visit 5 between the two sub-study groups (placebo or BCG) will be analyzed through the speed of the pulse wave velocity. Pulse wave velocity is measured in m/sec.

Measure: Differences in repeated measurements of angiometric parameters (arterial hardness) between the two sub-study groups in Visit 5

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)

---

Description: Differences in repeated measurements of central arterial pressures and reflected waves in visit 5 between the two sub-study groups (placebo or BCG) will be measured non-invasively by pulse wave analysis. Central arterial pressure is measured in mmHg.

Measure: Differences in repeated measurements of angiometric parameters (central arterial pressures and reflected waves) between the two sub-study groups in Visit 5

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)

---

Description: Differences in repeated measurements of thickness of the medial carotid sheath in visit 5 between the two sub-study groups (placebo or BCG) will be measured by B-mode ultrasound examination. Intima-Media Thickness is measured in mm

Measure: Differences in repeated measurements of angiometric parameters (thickness of the medial carotid sheath) between the two sub-study groups in Visit 5

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)

---

Description: Differences in repeated measurements of endothelial function in visit 5 between the two sub-study groups (placebo or BCG) will be measured by ultrasound measurement of endothelium-dependent flow-mediated dilatation and by nitrate-mediated dialatation. Endothelial function will be assessed by Flow Mediated Dilatation (FMD). Endothelium-dependent: diameter of the artery prior and after temporary ischemia in is measured in mm, nitrate-mediated: diameter of the artery prior and after nitrate administration is measured in mm

Measure: Differences in repeated measurements of angiometric parameters (endothelial function) between the two sub-study groups in Visit 5

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)

---

Description: Differences in cardiac ultrasound at visit 5 between the two sub-study groups (placebo or BCG) will be assessed using standard measurements from 2-D and Doppler echocardiography.

Measure: Differences in cardiac ultrasound at visit 5 between the two sub-study groups

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days), Visit 5 (180 +/- 5 days)

---

Description: Changes in the release of cytokines from blood mononuclear cells at visit 3 between the two sub-study groups (placebo or BCG) will be analyzed

Measure: Changes in the release of cytokines from blood mononuclear cells at visit 3 between the two sub-study groups

Time: Visit 1 (Day 0), Visit 3 (90 +/- 5 days)

---

Primary Outcomes

Description: Annual rate of the physiologically adjusted lung density change will be measured as the 15th percentile of the lung density measurements (PD15) as assessed by Computed Tomography (CT) densitometry at total lung capacity (TLC). CT lung density at the 15th percentile (PD15) is the threshold below which 15 percentage (%) of the voxels have lower densities and is used as the parameter for estimating the rate of lung density decline. Annual rate of the physiologically adjusted lung density change will be tested in a fixed comparision sequence 1. ARALAST NP 120 mg/kg BW/week group versus (vs) external placebo group, 2. ARALAST NP120 mg/kg BW/week vs 60 mg/kg BW/week, 3. ARALAST NP 60 mg/kg BW/week group vs external placebo group.

Measure: Annual Rate of the Physiologically Adjusted Lung Density Change

Time: Baseline, up to Week 104

---

Secondary Outcomes

Description: COPD exacerbations are defined as an acute worsening of respiratory symptoms that results in additional therapy and will be assessed according to the classification in GOLD criteria (2020) as follows: Moderate (treated with short acting bronchodilators [SABDs] plus antibiotics and/or oral corticosteroids) and Severe (required hospitalizations or a visit to the emergency room).

Measure: Number of Moderate or Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

Time: Baseline, up to Week 104

---

Description: Annual rate of change in post-bronchodilator FEV1 will be assessed.

Measure: Annual Rate of Change in Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

Time: Baseline, up to Week 104

---

Description: An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this IP or medicinal product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with an IP or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the IP or medicinal product. TEAE's will include related, serious adverse events (SAEs), suspected adverse reactions plus adverse reactions of interest, temporally-associated adverse events (AEs) with onset during infusion or within 24 hours following the end of IP infusion, and AEs resulting in changes to infusion dose.

Measure: Number of Participants with Treatment-Emergent Adverse Events (TEAE's)

Time: From Start of the study drug administration up to End of the study (up to Week 105)

---

Description: Number of participants who develop anti- A1PI antibodies following treatment with ARALAST NP will be assessed.

Measure: Number of Participants Who Develop Anti-A1PI Antibodies Following Treatment With ARALAST NP

Time: From Start of the study drug administration up to End of the study (up to Week 105)

---

Description: Plasma trough level of antigenic and functional A1PI for ARALAST NP at each dose level (ARALAST NP 60 mg/kg BW/week, ARALAST NP 120 mg/kg BW/week) will be assessed.

Measure: Plasma Trough Level of Antigenic and Functional A1PI for ARALAST NP at each dose Level

Time: Pre-dose, Weeks 4, 13, 28, 52, 78, 91, 104, 105

---

Primary Outcomes

Measure: Change From Baseline to the Primary Time Point in Forced Expiratory Volume in 1 Second (FEV1) Compared to Placebo

Time: From Baseline up to average of Weeks 13 and 14

---

Secondary Outcomes

Description: The EXACT (E-RS) scale is a participant-reported outcome (PRO) designed to measure the symptoms of participants with COPD. The E-RS utilizes 11 respiratory symptom items from the existing and validated 14-item EXACT, which measures symptoms of exacerbation. The E-RS total score quantifies respiratory symptom severity, and 3 domains assess breathlessness, cough and sputum, and chest symptoms. The E-RS will be collected on the daily e-diary, which will include all 14 items from the EXACT questionnaire.

Measure: Change From Baseline in the EXACT Respiratory Symptoms (E-RS) Daily Symptom Diary to the Primary Time Point

Time: One week prior to first dose through one week after the last dose.

---

Description: The CAT is an eight-item questionnaire that will be completed by the participant and is designed to quantify the impact of COPD symptoms on the health status of participants. The CAT provides a score of 0-40 to indicate the impact of the disease.

Measure: Change From Baseline in the COPD Assessment Test (CAT) to the Week 14 Time Point

Time: From Baseline up to Week 14

---

Description: The SGRQ is a participant completed, a disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in participants with obstructive airway disease. Scores of the SGRQ-C range from 0 to 100, with higher scores indicating more limitations.

Measure: Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) to the Week 14 Time Point

Time: From Baseline up to Week 14

---

Measure: Change from Baseline in Post-Bronchodilator FEV1

Time: From Baseline up to average of Weeks 13 and 14

---

Measure: Cmax: Maximum Observed Plasma Concentration for ION-827359

Time: Up to Week 24

---

Measure: Tmax: Time to Reach the Maximum Plasma Concentration for ION-827359

Time: Up to Week 24

---

Measure: AUC[0-t]: Area Under the Plasma Concentration-Time Curve from Time Zero to t for ION-827359

Time: Up to Week 24

---

Measure: Incidence of Participants With at Least One Treatment-Emergent Adverse Event (TEAE), Graded by Severity

Time: Up to Week 24

---

Measure: Number of Participants With Abnormal Laboratory Values

Time: Up to Week 24

---

Measure: Number of Participants With Abnormal Vital Signs Measurements

Time: Up to Week 24

---

Primary Outcomes

Description: Total number of people enrolled divided by the total number of people invited to participate (multiplied by 100 to calculate a percentage)

Measure: Recruitment Rate

Time: Pre-program (baseline)

---

Description: Percentage of people who completed the full program and all assessments

Measure: Completion Rate

Time: Through study completion, 12 weeks

---

Description: Percentage of people who attended program sessions (exercise and cognitive training components)

Measure: Attendance

Time: Throughout entire intervention (12 weeks, 2 sessions/week per group)

---

Description: Participant and instructors rating of program components and overall program (via hand-written questionnaire). Participants and instructors must rate their level of agreement (1 = strongly disagree, 2 = disagree, 3 = no opinion, 4 = agree, 5 = strongly agree) with various statements. The higher the rating, the greater the satisfaction. They also must rate if the difficulty of the program was optimal, somewhat easy or hard, or too easy or hard. They must also specify how much money they would be willing to spend on the program. They are also given an opportunity to record optional additional comments/recommendation.

Measure: Change in Participant and Instructor Rating of experience, satisfaction, and feasibility of program

Time: Mid-point (6 weeks) and post-program (12 weeks)

---

Description: Financial cost of running program (equipment purchased for study - cognitive training tablet and stands - and YMCA staff pay) as reported by researcher and YMCA staff

Measure: Cost of program

Time: Post-program (12 weeks)

---

Description: Self-reported biological sex (at birth) using basic demographics questionnaire

Measure: Sex

Time: Pre-program (baseline)

---

Description: One-on-one interview with researcher, answering broad questions about their experience in the program and study

Measure: Participant and Instructor perceived program experience and satisfaction

Time: Post-program (at 12 weeks)

---

Description: Experience of participants and instructors will also be observed by the researcher (observational notes will be taken by the researcher during each class). No names of participants and instructors will be recorded.

Measure: Participant and Instructor observer-perceived program experience and satisfaction

Time: Throughout entire intervention (12 weeks, 2 sessions/week per group)

---

Description: Self-reported years of formal education and training (training years for instructors only) using basic demographics questionnaire

Measure: Education

Time: Pre-program (baseline)

---

Description: Self-reported previous and current occupations using basic demographics questionnaire

Measure: Occupation

Time: Pre-program (baseline)

---

Description: Self-reported previous and current medical conditions using basic demographics questionnaire

Measure: Medical Condition

Time: Pre-program (baseline)

---

Description: Self-reported previous and current medications using basic demographics questionnaire

Measure: Medications

Time: Pre-program (baseline)

---

Description: Using the Montreal Cognitive Assessments (brief clinical tool) to assess visual/spatial abilities, working memory, executive functioning, language, abstraction, and orientation). Will be used to describe participants' baseline cognitive status (a score out of 30 is measured).

Measure: Montreal Cognitive Assessment (global cognitive function)

Time: Pre-program (baseline)

---

Description: Using the International Physical Activities Questionnaire (IPAQ) to assess physical activity level based on self-reported frequency and duration of job-related, house work-related, transportation-related, and leisure-related physical activities done in the past week. METS-minutes/week will be calculated and reported (i.e. take the number of minutes doing an activity in the past week and multiply by the appropriate metabolic equivalent, which will vary based on the intensity of the physical activity).

Measure: Physical Activity Level

Time: Pre-program (baseline)

---

Description: Using a cognitive activity scale (score of 0-4 per activity) that requires participants to self-report how often they typically engage in a variety of mentally stimulating activities (i.e. playing card games, reading, cooking, etc.) The more frequently they engage in the activity, the higher the score.

Measure: Participant cognitive activity

Time: Pre-program (baseline)

---

Description: Using a scale (score of 0-3 per group) that requires participants to self-report how often they typically interact (face-to-face or virtually) with different groups of people (i.e. their spouse, family, friends, co-workers, etc.). The more frequently they interact with the group, the higher the score.

Measure: Participant social activity

Time: Pre-program (baseline)

---

Description: Self-reported years of age using basic demographics questionnaire

Measure: Participant and Instructor Age

Time: Pre-program (baseline)

---

Secondary Outcomes

Description: STROOP task which assesses the length of time (seconds) it takes for a participant to correctly name a coloured square (test 1), read the name of a colour (test 2), and say the name of the colour that a word is printed in (test 3). Number of corrected and uncorrected errors are also recorded.

Measure: Change in Stroop Task Performance

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Trails Making Test Part A and B. Part A assesses visual search (participants must connect numbered circles in ascending numerical order (1-2-3-etc). Part B assesses working memory and task-switching (participants must connect circles in ascending numerical and alphabetical order (1-A-2-B- etc.). Time to complete the tests (second) and errors (number) made during the tests are recorded.

Measure: Change in Trail Making Task Performance

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Resting (seated) heart rate (beats per minute) using an automatic blood pressure cuff

Measure: Change in Resting Heart Rate

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Resting (seated) blood pressure (millimeters of mercury) using an automatic blood pressure cuff

Measure: Change in Resting Systolic and Diastolic Blood Pressure

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Using hand dynamometer (assessing grip strength in lbs) for right and left hand (two trials per hand)

Measure: Change in Grip Strength

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Weight (using automatic scale to measure in lbs, converted to kg) and height (measured in feet and inches, converted to meters) measured and combined to provide BMI (kg/m^2)

Measure: Change in Body Mass Index (BMI)

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Divide waist circumference (cm) by hip circumference (cm) to get ratio calculation

Measure: Change in Hip-to-Waist Circumference Ratio

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Agility and functional balance will be assessed using the Timed Up-and-Go (participants stand up from a chair, walk 6 meters, turn around an object, walk back to chair, and sit down). Time to complete test is measured (seconds) and assessor's observational notes of performance are taken.

Measure: Change in Timed Up-and-Go Performance

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Agility and functional balance will be assessed using the Four Square Step Test (participants must step over lines that are set up in a cross formation, creating 4 quadrants. They must step forward, backward, and side to side in a specific pattern (i.e. from quadrant 1 to quadrant 2, to quadrant 3, to quadrant 4). Time to complete test is recorded in seconds.

Measure: Change in Four Square Step Test Performance

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Lower body strength will be assessed using the 5 Time Sit-to-Stand (participants must complete 5 sit-to-stands from a chair as fast as they can). Time to complete all 5 is recorded in seconds.

Measure: Change in Sit-to-Stand Performance

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Functional fitness will be assessed using the 6 minute walk (participants walk along indoor track for 6 minutes). The number of laps achieved in 6 minutes is recorded. Assessor's observational notes of walking performance is also recorded.

Measure: Change in 6-minute walk test Performance

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Well-being will be self-reported using the "Vitality-Plus Scale" (self-reported general health questionnaire - rating of sleep quality, appetite, general energy level, etc.). Participants rate their degree of health on a scale from 1 - 5 (the higher the rating, the better their perceived overall well-being).

Measure: Change in Overall Well-being

Time: Pre-program (baseline) and post-program (12 weeks)

---

Description: Bandura Scale (named after the researcher who developed it) - self-reported rating of confidence (0 - 100%) to continue exercising routinely in various hypothetical situations (i.e. if one is sick, if the weather is poor, etc). The greater the confidence, the higher the score

Measure: Change in Exercise-related Self-Efficacy

Time: Pre-program (baseline) and post-program (12 weeks)

---

Primary Outcomes

Description: Change from baseline of Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h

Measure: Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h

Time: 12 weeks

---

Secondary Outcomes

Description: Change from baseline of Average FEV1 AUC0-4h post-dose at Week 12

Measure: Average FEV1 AUC0-4h post-dose at Week 12

Time: 12 weeks

---

Description: Change from baseline in Peak FEV1 over 4 hours post dose at Week 12

Measure: Peak FEV1 over 4 hours post dose at Week 12

Time: 12 weeks

---

Description: Change from baseline as a weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24

Measure: Weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24

Time: 24 weeks

---

Description: Change from baseline of SGRQ total score at Week 24

Measure: St. George's Respiratory Questionnaire (SGRQ) total score at Week 24

Time: 24 weeks

---

Description: Change from baseline of Morning trough FEV1 at Week 12

Measure: Morning trough FEV1 at Week 12

Time: 12 weeks

---

Description: The proportion of St. George's Respiratory Questionnaire (SGRQ) responders at Week 24.

Measure: St. George's Respiratory Questionnaire (SGRQ)

Time: 24 weeks

---

Description: Change from baseline of Rescue medication use at Week 24

Measure: Rescue medication use at Week 24

Time: 24 weeks

---

Description: Transitional Dyspnea Index (TDI) at Week 24

Measure: Transitional Dyspnea Index (TDI) at Week 24

Time: 24 weeks

---

Description: Change from baseline Evening trough FEV1 at Week 12

Measure: Evening trough FEV1 at Week 12

Time: 12 weeks

---

Description: Change from baseline Peak FEV1

Measure: Peak FEV1 at Week 6 and Week 24

Time: 6 and 24 weeks

---

Description: Change from baseline morning trough FEV1

Measure: Morning trough FEV1 at Week 6 and Week 24

Time: 6 and 24 weeks

---

Description: Change from baseline evening trough FEV1

Measure: Evening trough FEV1 at Week 6 and Week 24

Time: 6 and 24 weeks

---

Description: Change from baseline FEV1 AUC0-4h

Measure: FEV1 AUC0-4h at Week 6 and Week 24

Time: 6 and 24 weeks

---

Description: Change from baseline E-RS Total Score

Measure: Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 6 and Week 12

Time: 6 and 12 weeks

---

Description: Change from baseline SGRQ responder analysis

Measure: St. George's Respiratory Questionnaire (SGRQ) responder analysis at Week 6 and Week 12

Time: 6 and 12 weeks

---

Description: Change from baseline TDI

Measure: TDI at Week 6 and Week 12

Time: 6 and 12 Weeks

---

Description: Change from baseline of SGRQ total score at Weeks 6 and 12

Measure: St. George's Respiratory Questionnaire (SGRQ) total score at Weeks 6 and 12

Time: 6 Weeks and 12 weeks

---

Description: Change from baseline of Rescue medication use at Weeks 6 and 12

Measure: Rescue medication use at Weeks 6 and 12

Time: 12 weeks

---

Primary Outcomes

Description: Change from baseline of Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h

Measure: Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h

Time: 12 weeks

---

Secondary Outcomes

Description: Change from baseline of Average FEV1 AUC0-4h post-dose at Week 12

Measure: Average FEV1 AUC0-4h post-dose at Week 12

Time: 12 weeks

---

Description: Change from baseline of Peak FEV1 over 4 hours post-dose at Week 12

Measure: Peak FEV1 over 4 hours post-dose at Week 12

Time: 12 weeks

---

Description: Change from baseline as a weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24

Measure: Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24

Time: 24 weeks

---

Description: Change from baseline of SGRQ total score at Week 24

Measure: St. George's Respiratory Questionnaire (SGRQ) total score at Week 24

Time: 24 weeks

---

Description: Change from baseline of Morning trough FEV1 at Week 12

Measure: Morning trough FEV1 at Week 12

Time: 12 weeks

---

Description: The proportion of St. George's Respiratory Questionnaire (SGRQ) responders at Week 24.

Measure: St. George's Respiratory Questionnaire (SGRQ) responders at Week 24

Time: 24 weeks

---

Description: Change from baseline of Rescue medication use at Week 24

Measure: Rescue medication use at Week 24

Time: 24 weeks

---

Description: Transitional Dyspnea Index (TDI) at Week 24

Measure: Transitional Dyspnea Index (TDI) at Week 24

Time: 24 weeks

---

Description: Change from baseline Evening trough FEV1 at Week 12

Measure: Evening trough FEV1 at Week 12

Time: 12 weeks

---

Description: Change from baseline Peak FEV1

Measure: Peak FEV1 at Week 6 and Week 24

Time: 6 or 24 weeks

---

Description: Change from baseline morning trough FEV1

Measure: Morning trough FEV1 at Week 6 and Week 24

Time: 6 or 24 weeks

---

Description: Change from baseline evening trough FEV1

Measure: Evening trough FEV1 at Week 6 and Week 24

Time: 6 or 24 weeks

---

Description: Change from baseline FEV1 AUC0-4h

Measure: FEV1 AUC0-4h at Week 6 and Week 24

Time: 6 or 24 weeks

---

Description: Change from baseline E-RS Total Score

Measure: Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 6 and Week 12

Time: 6 or 12 weeks

---

Description: Change from baseline SGRQ responder analysis

Measure: SGRQ responder analysis at Week 6 and Week 12

Time: 6 or 12 weeks

---

Description: Change from baseline TDI

Measure: TDI at Week 6 and Week 12

Time: 6 or 12 weeks

---

Description: Change from baseline of SGRQ total score

Measure: St. George's Respiratory Questionnaire (SGRQ) total score at Weeks 6 and 12

Time: 6 or 12 weeks

---

Description: Change from baseline of Rescue medication use

Measure: Rescue medication use at Weeks 6 and 12

Time: 6 or 12 weeks

---

Primary Outcomes

Description: evaluate the efficacy of this device on reducing the number of COPD exacerbations, and/or COPD-related emergency department (ED) visits and hospitalizations, over a 12-month period compared with the previous 12 months

Measure: Efficacy of reducing COPD exacerbations as assessed by quantity of exacerbations seen in electronic medical record

Time: 2 years

---

Secondary Outcomes

Description: evaluate whether the use of myAirvo™2 may improve health-related quality of life (HRQoL) in COPD patients based on responses to the St. George's Respiratory Questionnaire - COPD (SGRQ-C). Higher scores on this measure indicate greater impairment.

Measure: COPD Health-related Quality of Life

Time: 1 year

---

Description: evaluate whether the use of myAirvo™2 may improve health-related quality of life (HRQoL) in COPD patients based on responses to the COPD Assessment Test (CAT). Higher scores on this measure indicate greater impairment.

Measure: COPD Health-related Quality of Life

Time: 1 year

---

Description: evaluate the efficacy of daily myAirvo™2 use on respiratory function using the Six Minute Walk Test

Measure: Respiratory function test results

Time: 1 year

---

Primary Outcomes

Description: AEs and SAEs will be collected.

Measure: Part A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: AEs and SAEs will be collected.

Measure: Part B: Number of participants with AEs and SAEs

Time: From start of the treatment (Day 0) to Day 18

---

Description: AEs and SAEs will be collected.

Measure: Part C: Number of participants with AEs and SAEs

Time: From start of the treatment (Day 0) to Day 8

---

Description: Blood samples will be collected for the assessment of hematology laboratory (lab) parameters.

Measure: Part A: Number of participants with clinically significant changes in hematology lab parameters

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Blood samples will be collected for the assessment of clinical chemistry lab parameters.

Measure: Part A: Number of participants with clinically significant changes in clinical chemistry lab parameters

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Urine samples will be collected for the assessment of urinalysis lab parameters.

Measure: Part A: Number of participants with clinically significant changes in urinalysis lab parameters

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Blood samples will be collected for the assessment of hematology lab parameters.

Measure: Part B: Number of participants with clinically significant changes in hematology lab parameters

Time: From start of the treatment (Day 0) to Day 18

---

Description: Blood samples will be collected for the assessment of clinical chemistry lab parameters.

Measure: Part B: Number of participants with clinically significant changes in clinical chemistry lab parameters

Time: From start of the treatment (Day 0) to Day 18

---

Description: Urine samples will be collected for the assessment of urinalysis lab parameters.

Measure: Part B: Number of participants with clinically significant changes in urinalysis lab parameters

Time: From start of the treatment (Day 0) to Day 18

---

Description: Blood samples will be collected for the assessment of hematology lab parameters.

Measure: Part C: Number of participants with clinically significant changes in hematology lab parameters

Time: From start of the treatment (Day 0) to Day 8

---

Description: Blood samples will be collected for the assessment of clinical chemistry lab parameters.

Measure: Part C: Number of participants with clinically significant changes in clinical chemistry lab parameters

Time: From start of the treatment (Day 0) to Day 8

---

Description: Urine samples will be collected for the assessment of urinalysis lab parameters.

Measure: Part C: Number of participants with clinically significant changes in urinalysis lab parameters

Time: From start of the treatment (Day 0) to Day 8

---

Description: Vital signs will be measured in a semi-supine position after atleast 10 minutes rest.

Measure: Part A: Number of participants with clinically significant vital signs

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Vital signs will be measured in a semi-supine position after atleast 10 minutes rest.

Measure: Part B: Number of participants with clinically significant vital signs

Time: From start of the treatment (Day 0) to Day 18

---

Description: Vital signs will be measured in a semi-supine position after atleast 10 minutes rest.

Measure: Part C: Number of participants with clinically significant vital signs

Time: From start of the treatment (Day 0) to Day 8

---

Description: Twelve-lead electrocardiogram will be performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and corrected QT intervals (QTc). The QT interval will be corrected for heart rate by Fredericia's formula (QTcF).

Measure: Part A: Number of participants with clinically significant abnormalities in 12-Lead electrocardiogram (ECG) findings

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Twelve-lead electrocardiogram will be performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTc.

Measure: Part B: Number of participants with clinically significant abnormalities in 12-Lead ECG findings

Time: From start of the treatment (Day 0) to Day 18

---

Description: Twelve-lead electrocardiogram will be performed in a semi-supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTc.

Measure: Part C: Number of participants with clinically significant abnormalities in 12-Lead ECG findings

Time: From start of the treatment (Day 0) to Day 8

---

Description: Spirometry measurements including forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) will be assessed

Measure: Part A: Number of participants with clinically significant abnormalities in spirometry measurements

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Spirometry measurements including FEV1 and FVC will be assessed.

Measure: Part B: Number of participants with clinically significant abnormalities in spirometry measurements

Time: From start of the treatment (Day 0) to Day 18

---

Description: Spirometry measurements including FEV1 and FVC will be assessed.

Measure: Part C: Number of participants with clinically significant abnormalities in spirometry measurements

Time: From start of the treatment (Day 0) to Day 8

---

Secondary Outcomes

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part A, Cohort 1 and 2: Area under the plasma GSK3923868 concentration versus time curve from time zero to last quantifiable concentration (AUC[0-t])

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Blood samples will be collected for the concentration of GSK3923868.

Measure: Part A, Cohort 1 and 2: Area under the plasma GSK3923868 concentration versus time curve from time zero to infinity (AUC[0-inf])

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part A, Cohort 1 and 2: Maximum observed GSK3923868 plasma concentration (Cmax)

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part A, Cohort 1 and 2: Time to maximum observed plasma drug concentration (Tmax)

Time: From start of the treatment (Day 0) to Day 2 in each treatment period

---

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part B, Cohort 3 and 4: AUC from time 0 (predose) to time tau (AUC [0-tau]) (tau=24hours for once a day dosing regimen) of GSK3923868 on Day 1 and Day 14

Time: Day 1 and 14: Up to 24 hours post dose

---

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part B, Cohort 3 and 4: Cmax of GSK3923868 on Day 1 and Day 14

Time: Day 1 and Day 14

---

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part B, Cohort 3 and 4: Tmax of GSK3923868 on Day 1 and Day 14

Time: Day 1 and Day 14

---

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part C: AUC (0-tau) (tau=24hours for once a day dosing regimen)of GSK3923868 on Day 1 and Day 7

Time: Day 1 and 7: Up to 24 hours post dose

---

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part C: Cmax of GSK3923868 on Day 1 and Day 7

Time: Day 1 and Day 7

---

Description: Blood samples will be collected for the concentrations of GSK3923868.

Measure: Part C: Tmax of GSK3923868 on Day 1 and Day 7

Time: Day 1 and Day 7

---

Primary Outcomes

Description: Evaluation of the relative bioavailability between the test formulations and the reference formulation for fixed dose combinations (FDCs) of BGF when delivered as BGF MDI with 3 different propellants by Cmax.

Measure: Maximum observed concentration (Cmax) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Evaluation of the relative bioavailability between the test formulations and the reference formulation for FDCs of BGF when delivered as BGF MDI with 3 different propellants by AUCinf.

Measure: Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Evaluation of the relative bioavailability between the test formulations and the reference formulation for FDCs of BGF when delivered as BGF MDI with 3 different propellants by AUClast.

Measure: Area under the plasma concentration- curve from time zero to the time of last quantifiable concentration (AUClast) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Secondary Outcomes

Description: Assessment of the pharmacokinetic (PK) parameters of BGF when administered as 3 different propellant formulations by tmax.

Measure: Time to reach maximum observed concentration (tmax) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by t½λz.

Measure: Terminal elimination half-life (t½λz) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by MRT.

Measure: Mean residence time in the systemic circulation extrapolated to infinity (MRT) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by λz.

Measure: Terminal elimination rate constant, estimated by log-linear least squares regression of the terminal part of the concentration-time curve (λz) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by CL/F.

Measure: Apparent total body clearance of drug after extravascular administration (CL/F) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by Vz/F.

Measure: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by TRCmax.

Measure: Treatment ratio for Cmax derived by dividing the Cmax of the test treatment by the reference treatment (TRCmax) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by TRAUCinf.

Measure: Treatment ratio for AUCinf, derived by dividing the AUCinf of the test treatment by the reference treatment (TRAUCinf) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Assessment of the PK parameters of BGF when administered as 3 different propellant formulations by TRAUClast.

Measure: Treatment ratio for AUClast derived by dividing the AUClast of the test treatment by the reference treatment (TRAUClast) of BGF MDI

Time: Pre-dose and 2, 5, 10, 20, 30, and 45 minutes post-dose and 1, 2, 4, 8, 12 and 24 hours post-dose

---

Description: Assessment of the safety and tolerability of a combination of BGF when administered as single doses in 3 different propellant formulations in healthy participants.

Measure: Number of participants with serious adverse events (SAE) and non-serious adverse events

Time: Screening (Only SAE), Days -1, 1, and Day 2 until Follow-up visit (approximately 3 to 7 days post final dose)

---